EGFR and lung adenocarcinoma: In addition, the effect of the use of TKIs was not negligible, though no significant difference was observed between patients who received TKI-therapy for EGFR/ALK-positive lung-adenocarcinoma and the other patients in terms of either BTR-distant or BTR-all in the present study.